Toll Free: 1-888-928-9744

Wilms' Tumor (Nephroblastoma) Global Clinical Trials Review, H1, 2016

Published: May 31, 2016 | Pages: 93 | Publisher: GlobalData | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Wilms' Tumor (Nephroblastoma) Global Clinical Trials Review, H1, 2016

Summary

GlobalData's clinical trial report, "Wilms' Tumor (Nephroblastoma) Global Clinical Trials Review, H1, 2016" provides an overview of Wilms' Tumor (Nephroblastoma) clinical trials scenario. This report provides top line data relating to the clinical trials on Wilms' Tumor (Nephroblastoma). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons To Buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
 Table of Contents
Table of Contents 2 List of Tables 3 List of Figures 4 Report Guidance 5 Clinical Trials by Region 6 Clinical Trials and Average Enrollment by Country 7 Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9 Top Five Countries Contributing to Clinical Trials in Europe 10 Top Countries Contributing to Clinical Trials in North America 11 Top Five Countries Contributing to Clinical Trials in Middle East and Africa 12 Top Countries Contributing to Clinical Trials in Central and South America 13 Clinical Trials by G7 Countries: Proportion of Wilms' Tumor (Nephroblastoma) to Oncology Clinical Trials 14 Clinical Trials by Phase in G7 Countries 15 Clinical Trials in G7 Countries by Trial Status 16 Clinical Trials by E7 Countries: Proportion of Wilms' Tumor (Nephroblastoma) to Oncology Clinical Trials 17 Clinical Trials by Phase 18 In Progress Trials by Phase 19 Clinical Trials by Trial Status 20 Clinical Trials by End Point Status 21 Subjects Recruited Over a Period of Time 22 Clinical Trials by Sponsor Type 23 Prominent Sponsors 24 Top Companies Participating in Wilms' Tumor (Nephroblastoma) Therapeutics Clinical Trials 25 Prominent Drugs 27 Latest Clinical Trials News on Wilms' Tumor (Nephroblastoma) 28 Apr 14, 2016: Juno Therapeutics Announces First clinical data for the WT-1 TCR product candidate, JTCR016 at the American Association for Cancer Research Annual Meeting 28 Clinical Trial Profile Snapshots 29 Appendix 90 Abbreviations 90 Definitions 90 Research Methodology 91 Secondary Research 91 About GlobalData 92 Contact Us 92 Disclaimer 92 Source 93
List of Tables
Wilms' Tumor (Nephroblastoma) Therapeutics, Global, Clinical Trials by Region, 2016* 6 Wilms' Tumor (Nephroblastoma) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7 Wilms' Tumor (Nephroblastoma) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8 Wilms' Tumor (Nephroblastoma) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 9 Wilms' Tumor (Nephroblastoma) Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10 Wilms' Tumor (Nephroblastoma) Therapeutics Clinical Trials, North America, Top Countries, 2016* 11 Wilms' Tumor (Nephroblastoma) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016* 12 Wilms' Tumor (Nephroblastoma) Therapeutics Clinical Trials, Central and South America, Top Countries, 2016* 13 Proportion of Wilms' Tumor (Nephroblastoma) to Oncology Clinical Trials, G7 Countries (%), 2016* 14 Wilms' Tumor (Nephroblastoma) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15 Wilms' Tumor (Nephroblastoma) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16 Proportion of Wilms' Tumor (Nephroblastoma) to Oncology Clinical Trials, E7 Countries (%), 2016* 17 Wilms' Tumor (Nephroblastoma) Therapeutics, Global, Clinical Trials by Phase, 2016* 18 Wilms' Tumor (Nephroblastoma) Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 19 Wilms' Tumor (Nephroblastoma) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 20 Wilms' Tumor (Nephroblastoma) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 21 Wilms' Tumor (Nephroblastoma) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 22 Wilms' Tumor (Nephroblastoma) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 23 Wilms' Tumor (Nephroblastoma) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 24 Wilms' Tumor (Nephroblastoma) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 26 Wilms' Tumor (Nephroblastoma) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 27


List of Figures
Wilms' Tumor (Nephroblastoma) Therapeutics, Global, Clinical Trials by Region (%), 2016* 6 Wilms' Tumor (Nephroblastoma) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7 Wilms' Tumor (Nephroblastoma) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8 Wilms' Tumor (Nephroblastoma) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 9 Wilms' Tumor (Nephroblastoma) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10 Wilms' Tumor (Nephroblastoma) Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11 Wilms' Tumor (Nephroblastoma) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016* 12 Wilms' Tumor (Nephroblastoma) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2016* 13 Proportion of Wilms' Tumor (Nephroblastoma) to Oncology Clinical Trials, G7 Countries (%), 2016* 14 Wilms' Tumor (Nephroblastoma) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15 Wilms' Tumor (Nephroblastoma) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16 Proportion of Wilms' Tumor (Nephroblastoma) to Oncology Clinical Trials, E7 Countries (%), 2016* 17 Wilms' Tumor (Nephroblastoma) Therapeutics, Global, Clinical Trials by Phase (%), 2016* 18 Wilms' Tumor (Nephroblastoma) Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 19 Wilms' Tumor (Nephroblastoma) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 20 Wilms' Tumor (Nephroblastoma) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 21 Wilms' Tumor (Nephroblastoma) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 22 Wilms' Tumor (Nephroblastoma) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 23 Wilms' Tumor (Nephroblastoma) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 24 Wilms' Tumor (Nephroblastoma) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 25 Wilms' Tumor (Nephroblastoma) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 27 GlobalData Methodology 91

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global Biocides market size is likely to be valued at USD 11.9 billion by 2022; as per a new research report by Radiant Insights, Inc. Growth in water treatment process units particularly in China, Japan and India is likely to drive demand. Increasin

Read More...

Global polymethyl methacrylate (PMMA) market size is likely to be valued at USD 11.65 billion by 2022; as per a new research report by Radiant Insights, Inc. Increasing spending on advertising & marketing for building strong brand equity and product

Read More...

Global contact lenses market size is estimated to reach USD 12.5 billion by 2020, according to a new industry report by Radiant Insights, Inc. Growing number of ophthalmic disorder observed in global population especially children is likely to drive

Read More...

Global engineering service outsourcing market size is likely to be valued at USD 415.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Rapid alignment of OEMs accompanied by increasing focus on efficient performance and reliab

Read More...

Global aerosol propellants market is anticipated to reach USD 24.8 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing popularity of personal care and cosmetics products such as hair sprays, deodorants and shaving cream

Read More...
Choose License Type
Single User - US $2500
Multi User - US $5000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify